# Can-fite Biopharma (CANF) — Earnings

CANF · AMEX · Stock

Canonical page: https://www.lighthorse.io/tickers/canf/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q4 2023 |
| Period end | Dec 31, 2023 |
| EPS actual | −$0.40 |
| EPS estimate | −$0.27 |
| EPS surprise | −49.06% |
| Revenue surprise | −11.25% |
| Revenue | $177,500.00 |
| Revenue estimate | $200,000.00 |
| Reported | Mar 28, 2024 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1536196/000121390024026876/ea0202798-6k_canfite.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q4 2023 | Mar 28, 2024 | −$0.27 | −$0.40 | -49.06% | $200,000.00 | $177,500.00 |
| Q3 2023 | Nov 30, 2023 | −$0.43 | −$0.27 | 38.37% | $200,000.00 | $198,000.00 |
| Q2 2023 | Aug 31, 2023 | −$0.62 | −$0.35 | 43.25% | $200,000.00 | $198,000.00 |
| Q1 2023 | Jun 1, 2023 | −$0.71 | $0.00 | 100.00% | — | $196,000.00 |
| Q4 2022 | Mar 30, 2023 | −$0.91 | −$1.11 | -21.46% | $500,000.00 | $200,000.00 |
| Q3 2022 | Nov 25, 2022 | −$0.90 | −$0.93 | -3.24% | $300,000.00 | $204,000.00 |
| Q2 2022 | Aug 25, 2022 | −$0.73 | −$0.80 | -9.09% | $250,000.00 | $409,000.00 |
| Q1 2022 | May 26, 2022 | −$1.40 | $0.00 | 100.00% | $133,333.00 | $205,000.00 |
| Q4 2021 | Mar 24, 2022 | −$1.70 | −$3.00 | -76.47% | $266,667.00 | $204,000.00 |
| Q3 2021 | Nov 26, 2021 | −$0.70 | −$1.90 | -171.44% | $140,000.00 | $251,500.00 |
| Q2 2021 | Aug 26, 2021 | −$1.55 | −$1.20 | 22.58% | $218,333.00 | $250,000.00 |
| Q1 2021 | May 27, 2021 | −$1.35 | $0.00 | 100.00% | $300,000.00 | $148,000.00 |
| Q4 2020 | Mar 25, 2021 | −$1.35 | −$2.40 | -77.78% | $500,000.00 | $175,000.00 |
| Q3 2020 | Nov 30, 2020 | −$2.35 | −$1.60 | 31.92% | $500,000.00 | $205,500.00 |
| Q2 2020 | Aug 27, 2020 | −$2.50 | −$3.00 | -19.99% | $250,000.00 | $302,000.00 |
| Q1 2020 | Jun 1, 2020 | −$4.15 | −$9.01 | -116.89% | $500,000.00 | $198,000.00 |

## Frequently Asked Questions

### When did Can-fite Biopharma (CANF) last report earnings?

Can-fite Biopharma last reported on Mar 28, 2024, covering fiscal Q4 2023.

### Did CANF beat earnings estimates?

No. Can-fite Biopharma reported EPS of −$0.40 for Q4 2023 against a −$0.27 estimate — a 49.06% miss.

### How much revenue did CANF report last quarter?

Can-fite Biopharma reported $177,500.00 in revenue for Q4 2023, against a consensus estimate of $200,000.00.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).